| Abstract: |
Lymphomas represent the third most common cancer in children and adolescents. The non-Hodgkin's lymphomas comprise a heterogeneous group of tumors, with distinct clinical and pathologic features. Although intensive multi-agent chemotherapy has made non-Hodgkin's lymphoma one of the most curable malignancies in children and young adults, there is room for improvement in treatment, particularly for those with advanced-stage disease and those who relapse after conventional therapy. New approaches are now attempting to reduce the burden of treatment, to focus on novel and more specific biologic targets, and to improve outcomes for patients with advanced-stage disease while reducing the potential for late effects. A comprehensive review of all potential agents is beyond the scope of this review, which will focus on some of the newer strategies for treating non-Hodgkin's lymphoma that are coming into clinical use today. © 2010 Springer Science+Business Media, LLC. |
| Keywords: |
adolescent; child; unclassified drug; histone deacetylase inhibitor; prednisone; review; sorafenib; doxorubicin; erlotinib; sunitinib; cancer combination chemotherapy; cytarabine; ibritumomab tiuxetan; methotrexate; rituximab; drug megadose; cancer diagnosis; unindexed drug; bortezomib; mantle cell lymphoma; etoposide; cyclophosphamide; nucleoside analog; vincristine; cysteine proteinase inhibitors; diagnostic imaging; vinblastine; childhood cancer; monoclonal antibodies; monoclonal antibody; protein tyrosine kinase inhibitor; protein kinase inhibitors; antibodies, monoclonal; hematologic malignancy; nonhodgkin lymphoma; non-hodgkin's lymphoma; lymphoma, non-hodgkin; lymphoma; cediranib; histone deacetylase inhibitors; precursor cell lymphoblastic leukemia-lymphoma; targeted therapy; cancer epidemiology; large cell lymphoma; lymphoma, large b-cell, diffuse; acute lymphocytic leukemia; obatoclax; oblimersen; salinosporamide a; proteinase inhibitor; burkitt lymphoma; myeloma; pediatrics; tositumomab; tnf-related apoptosis-inducing ligand; 3 [1 (2,6 dichloro 3 fluorophenyl)ethoxy] 5 [1 (4 piperidinyl) 1h pyrazol 4 yl] 2 pyridinylamine; small molecule inhibitors; epratuzumab; inotuzumab ozogamicin; monoclonal antibody sgn 35; sgn 30; lymphoblastoma; lymphoma, large-cell, anaplastic; purine-nucleoside phosphorylase
|
